Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning. Verge has created a proprietary all-in-human platform, featuring one of the field’s largest and most comprehensive databases of neurodegenerative patient genomic data. The company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson’s disease toward the clinic and became on the of the first AI-focused therapeutic companies to begin human trials. In 2022 Verge signed a partnership agreement with Eli Lilly worth potentially $750M+. Fitz Gate invested in Verge’s Series A alongside Draper and Threshold Ventures. One year later Blackrock led the company’s $80M Series B with participation by Eli Lilly and others.
